Merck & Co. Faces Legal Challenge for Keytruda SC Distribution in Germany

Merck & Co Faces Legal Setback Over Keytruda SC in Germany

Merck & Co. encounters a significant legal challenge as a German court issues a preliminary injunction against the distribution of its subcutaneous version of Keytruda (Keytruda SC). This ruling by the Munich Regional Court halts Merck's launch activities in Germany, citing an imminent infringement of Halozyme Therapeutics' MDASE™ patent (European Patent No. 2 797 622). The injunction underscores the growing tension in the pharmaceutical landscape surrounding patent rights, particularly as companies innovate drug delivery technologies to improve patient outcomes. Merck's ongoing nullity proceedings initiated in August 2025 before the German Federal Patent Court may influence the future of its Keytruda SC offering, but for now, the company must navigate the implications of this court decision.

Mark Snyder, Chief Legal Officer of Halozyme, expresses confidence that the injunction will hold through any appeals, reinforcing Halozyme’s commitment to protecting its MDASE patents. These patents are critical for enabling rapid subcutaneous drug delivery, a method that enhances patient convenience and compliance. While patients can still access the intravenous version of Keytruda, the injunction complicates Merck's strategy in Germany, a key market for its cancer immunotherapy. This legal action signals the importance of intellectual property rights in the competitive biopharmaceutical arena, where innovations in drug formulation can lead to substantial commercial advantages.

The case highlights the broader context of Halozyme's efforts to safeguard its MDASE technology, not only in Germany but also through a lawsuit in U.S. federal court, where it alleges that Merck's subcutaneous version of Keytruda infringes on 15 patents related to its MDASE technology. This multi-national legal strategy reflects Halozyme's proactive approach to defending its intellectual property, ensuring that its innovations in drug delivery continue to benefit patients. Despite the ongoing litigation, Halozyme remains committed to advancing its drug delivery technology, which is crucial for improving therapeutic efficiency and patient care.

In a related note, Pliant Therapeutics is attracting attention in the biotech sector due to promising trial results for its innovative cancer therapy. Despite recent stock volatility, the encouraging outcomes in specific cancer treatments raise hopes for the therapy’s market potential. As Pliant navigates the complexities of clinical development and regulatory approval, stakeholders remain vigilant about the company’s ability to capitalize on its scientific advancements amid the unpredictable nature of the biotech industry.